206 related articles for article (PubMed ID: 30322893)
1. Identification of therapeutic targets in chordoma through comprehensive genomic and transcriptomic analyses.
Liang WS; Dardis C; Helland A; Sekar S; Adkins J; Cuyugan L; Enriquez D; Byron S; Little AS
Cold Spring Harb Mol Case Stud; 2018 Dec; 4(6):. PubMed ID: 30322893
[TBL] [Abstract][Full Text] [Related]
2. Preclinical Characterization of Novel Chordoma Cell Systems and Their Targeting by Pharmocological Inhibitors of the CDK4/6 Cell-Cycle Pathway.
von Witzleben A; Goerttler LT; Marienfeld R; Barth H; Lechel A; Mellert K; Böhm M; Kornmann M; Mayer-Steinacker R; von Baer A; Schultheiss M; Flanagan AM; Möller P; Brüderlein S; Barth TF
Cancer Res; 2015 Sep; 75(18):3823-31. PubMed ID: 26183925
[TBL] [Abstract][Full Text] [Related]
3. Defective homologous recombination DNA repair as therapeutic target in advanced chordoma.
Gröschel S; Hübschmann D; Raimondi F; Horak P; Warsow G; Fröhlich M; Klink B; Gieldon L; Hutter B; Kleinheinz K; Bonekamp D; Marschal O; Chudasama P; Mika J; Groth M; Uhrig S; Krämer S; Heining C; Heilig CE; Richter D; Reisinger E; Pfütze K; Eils R; Wolf S; von Kalle C; Brandts C; Scholl C; Weichert W; Richter S; Bauer S; Penzel R; Schröck E; Stenzinger A; Schlenk RF; Brors B; Russell RB; Glimm H; Schlesner M; Fröhling S
Nat Commun; 2019 Apr; 10(1):1635. PubMed ID: 30967556
[TBL] [Abstract][Full Text] [Related]
4. A retrospective study on the mechanism underlying quick transfer from response to resistance in a repeated recurrent chordoma patient with molecular alterations treated with Palbociclib.
Zhong N; Yu D; Yang M; Lu X; Zhang Q; Wei W; Jiao J; Yang X; Zhu Z; Chen S; Xiao J
J Cancer Res Clin Oncol; 2024 Feb; 150(2):95. PubMed ID: 38369555
[TBL] [Abstract][Full Text] [Related]
5. Whole genome sequencing of skull-base chordoma reveals genomic alterations associated with recurrence and chordoma-specific survival.
Bai J; Shi J; Li C; Wang S; Zhang T; Hua X; Zhu B; Koka H; Wu HH; Song L; Wang D; Wang M; Zhou W; Ballew BJ; Zhu B; Hicks B; Mirabello L; Parry DM; Zhai Y; Li M; Du J; Wang J; Zhang S; Liu Q; Zhao P; Gui S; Goldstein AM; Zhang Y; Yang XR
Nat Commun; 2021 Feb; 12(1):757. PubMed ID: 33536423
[TBL] [Abstract][Full Text] [Related]
6. Loss of DNA Damage Response in Neuroblastoma and Utility of a PARP Inhibitor.
Takagi M; Yoshida M; Nemoto Y; Tamaichi H; Tsuchida R; Seki M; Uryu K; Nishii R; Miyamoto S; Saito M; Hanada R; Kaneko H; Miyano S; Kataoka K; Yoshida K; Ohira M; Hayashi Y; Nakagawara A; Ogawa S; Mizutani S; Takita J
J Natl Cancer Inst; 2017 Nov; 109(11):. PubMed ID: 29059438
[TBL] [Abstract][Full Text] [Related]
7. Genomic and transcriptomic characterization of skull base chordoma.
Sa JK; Lee IH; Hong SD; Kong DS; Nam DH
Oncotarget; 2017 Jan; 8(1):1321-1328. PubMed ID: 27901492
[TBL] [Abstract][Full Text] [Related]
8. Genomic aberrations frequently alter chromatin regulatory genes in chordoma.
Wang L; Zehir A; Nafa K; Zhou N; Berger MF; Casanova J; Sadowska J; Lu C; Allis CD; Gounder M; Chandhanayingyong C; Ladanyi M; Boland PJ; Hameed M
Genes Chromosomes Cancer; 2016 Jul; 55(7):591-600. PubMed ID: 27072194
[TBL] [Abstract][Full Text] [Related]
9. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
[TBL] [Abstract][Full Text] [Related]
10. Efficiency of olaparib in colorectal cancer patients with an alteration of the homologous repair protein.
Ghiringhelli F; Richard C; Chevrier S; Végran F; Boidot R
World J Gastroenterol; 2016 Dec; 22(48):10680-10686. PubMed ID: 28082821
[TBL] [Abstract][Full Text] [Related]
11. Integrated genomic and transcriptomic analysis of human brain metastases identifies alterations of potential clinical significance.
Saunus JM; Quinn MC; Patch AM; Pearson JV; Bailey PJ; Nones K; McCart Reed AE; Miller D; Wilson PJ; Al-Ejeh F; Mariasegaram M; Lau Q; Withers T; Jeffree RL; Reid LE; Da Silva L; Matsika A; Niland CM; Cummings MC; Bruxner TJ; Christ AN; Harliwong I; Idrisoglu S; Manning S; Nourse C; Nourbakhsh E; Wani S; Anderson MJ; Fink JL; Holmes O; Kazakoff S; Leonard C; Newell F; Taylor D; Waddell N; Wood S; Xu Q; Kassahn KS; Narayanan V; Taib NA; Teo SH; Chow YP; kConFab ; Jat PS; Brandner S; Flanagan AM; Khanna KK; Chenevix-Trench G; Grimmond SM; Simpson PT; Waddell N; Lakhani SR
J Pathol; 2015 Nov; 237(3):363-78. PubMed ID: 26172396
[TBL] [Abstract][Full Text] [Related]
12. High-resolution whole-genome analysis of skull base chordomas implicates FHIT loss in chordoma pathogenesis.
Diaz RJ; Guduk M; Romagnuolo R; Smith CA; Northcott P; Shih D; Berisha F; Flanagan A; Munoz DG; Cusimano MD; Pamir MN; Rutka JT
Neoplasia; 2012 Sep; 14(9):788-98. PubMed ID: 23019410
[TBL] [Abstract][Full Text] [Related]
13. Emerging Therapeutic Targets in Chordomas: A Review of the Literature in the Genomic Era.
Gill CM; Fowkes M; Shrivastava RK
Neurosurgery; 2020 Feb; 86(2):E118-E123. PubMed ID: 31504814
[TBL] [Abstract][Full Text] [Related]
14. CDK4 expression in chordoma: A potential therapeutic target.
Liu T; Shen JK; Choy E; Zhang Y; Mankin HJ; Hornicek FJ; Duan Z
J Orthop Res; 2018 Jun; 36(6):1581-1589. PubMed ID: 29194728
[TBL] [Abstract][Full Text] [Related]
15. Whole-transcriptome analysis of chordoma of the skull base.
Bell D; Raza SM; Bell AH; Fuller GN; DeMonte F
Virchows Arch; 2016 Oct; 469(4):439-49. PubMed ID: 27401718
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive genomic profiling of head and neck squamous cell carcinoma reveals FGFR1 amplifications and tumour genomic alterations burden as prognostic biomarkers of survival.
Dubot C; Bernard V; Sablin MP; Vacher S; Chemlali W; Schnitzler A; Pierron G; Ait Rais K; Bessoltane N; Jeannot E; Klijanienko J; Mariani O; Jouffroy T; Calugaru V; Hoffmann C; Lesnik M; Badois N; Berger F; Le Tourneau C; Kamal M; Bieche I
Eur J Cancer; 2018 Mar; 91():47-55. PubMed ID: 29331751
[TBL] [Abstract][Full Text] [Related]
17. Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer.
Formisano L; Lu Y; Servetto A; Hanker AB; Jansen VM; Bauer JA; Sudhan DR; Guerrero-Zotano AL; Croessmann S; Guo Y; Ericsson PG; Lee KM; Nixon MJ; Schwarz LJ; Sanders ME; Dugger TC; Cruz MR; Behdad A; Cristofanilli M; Bardia A; O'Shaughnessy J; Nagy RJ; Lanman RB; Solovieff N; He W; Miller M; Su F; Shyr Y; Mayer IA; Balko JM; Arteaga CL
Nat Commun; 2019 Mar; 10(1):1373. PubMed ID: 30914635
[TBL] [Abstract][Full Text] [Related]
18. A comparison of cell-cycle markers in skull base and sacral chordomas.
Yakkioui Y; Temel Y; Creytens D; Jahanshahi A; Fleischeuer R; Santegoeds RG; Van Overbeeke JJ
World Neurosurg; 2014; 82(1-2):e311-8. PubMed ID: 23416769
[TBL] [Abstract][Full Text] [Related]
19. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
20. Genomic profiling of pelvic genital type leiomyosarcoma in a woman with a germline
Thibodeau ML; Reisle C; Zhao E; Martin LA; Alwelaie Y; Mungall KL; Ch'ng C; Thomas R; Ng T; Yip S; J Lim H; Sun S; Young SS; Karsan A; Zhao Y; Mungall AJ; Moore RA; J Renouf D; Gelmon K; Ma YP; Hayes M; Laskin J; Marra MA; Schrader KA; Jones SJM
Cold Spring Harb Mol Case Stud; 2017 Sep; 3(5):. PubMed ID: 28514723
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]